All In Biotech

Drug Trial Radar · NCT06112756

A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause

A Randomized, Parallel-group Treatment, Phase 2, Double-blind Pilot Study to Investigate the Efficacy and Safety of Elinzanetant Compared With Placebo for Treatment of Sleep Disturbances Associated With Menopause.

Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

Nov 8, 2023

Primary completion

Aug 22, 2024

Study completion Nov 7, 2024

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Nov 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause. Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop. Sleep disturbances, for example, frequent waking up at night, are a common and bothersome symptom associated with menopause that affects women's quality of life. The study treatment Elinzanetant (also called BAY 3427080) is under development to treat symptoms like hot flashes which are caused by hormonal changes associated with menopause. It may block the activity of a protein that has been found to contribute to sleep disturbances. The main purpose of this study is to learn how does elinzanetant affect sleep disturbances associated with menopause as measured on a sleep test called polysomnography (PSG) as compared with placebo. For this, the researchers will analyze * change in the total number of minutes a participant wakes up at night after going to sleep after 4 weeks of treatment compared to before treatment * change in the total number of minutes a participant wakes up at night after going to sleep after 12 weeks of treatment compared to before treatment * change in the participant's total time asleep while in bed after 4 and 12 weeks of treatment compared to before treatment. The study participants will be randomly (by chance) assigned to one of two treatment groups. Dependent on the group, they will take elinzanetant or placebo for 12 weeks. Each participant will be in the study for approximately 22 weeks (plus potential washout period), including a screening phase of up to 6 weeks, 12 weeks of treatment, and a follow up phase of 4 weeks after the end of treatment. 5 visits to the study site are planned. During the study, the doctors and their study team will: * take blood and urine samples * do physical examinations * check vital signs * do sleep tests * use an electronic hand-held device to record sleep quality and hot flashes at home An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

Conditions

  • Sleep Disturbances Associated With Menopause

Interventions

  • ElinzanetantDrug

    Oral

  • PlaceboOther

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG)Time frame: From baseline until week 4

Locations

40 sites in 7 countries. Site status is shown where the registry gives one.

  • Preferred Research Partners

    Little Port Walter, Alaska

  • MomDoc Women's Health Research | Scottsdale, AZ

    Scottsdale, Arizona

  • Diagnamics | Encinitas, CA

    Encinitas, California

  • SDS Clinical Trials Inc

    Santa Ana, California

  • Pacific Clinical Research Management Group LLC

    Upland, California

  • Helix Biomedics LLC | Boynton Beach, FL

    Boynton Beach, Florida

  • Sweet Hope Research Specialty, Inc. - Hialeah

    Hialeah, Florida

  • PharmaDev Clinical Research Institute, LLC

    Miami, Florida

  • Segal Trials - Women's Health & General Medicine Research Site

    North Miami, Florida

  • Palm Beach Research center

    West Palm Beach, Florida

  • Sleep Practitioners, LLC

    Macon, Georgia

  • SleepCare Research Institute Inc

    Stockbridge, Georgia

  • Brengle Family Medicine

    Indianapolis, Indiana

  • Revive Research Institute, Inc. - Women's Health

    Dearborn Heights, Michigan

  • Essential Women's Health Associates

    Las Vegas, Nevada

  • Clinilabs Drug Development Corporation-Feasibility

    Eatontown, New Jersey

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • Intrepid Research, LLC.

    Cincinnati, Ohio

  • Bogan Sleep Consultants, LLC

    Columbia, South Carolina

  • FutureSearch Trials of Neurology LP

    Austin, Texas

  • Sleep Therapy and Research Center | Medical Center Drive Office

    San Antonio, Texas

  • Road Runner Research, Ltd.

    San Antonio, Texas

  • EMCO Privatklinik

    Bad Dürrnberg, State of Salzburg, Austria

  • Anima Research Center

    Alken, Belgium

  • SGS CPU

    Edegem, Belgium

  • Pneumocare SRL

    Erpent, Belgium

  • Universitair Ziekenhuis Leuven | Gasthuisberg Campus - Sleep Centre

    Leuven, Belgium

  • Národní ústav duševního zdraví

    Klecany, Czechia

  • ADVANCED SLEEP RESEARCH BERLIN Berlin

    Berlin, Germany

  • KLIN FORSCHUNG HAMBURG GMBH Hamburg

    Hamburg, Germany

  • SOMNI BENE INSTITUT FUR MEDIZIMISCHE FORSCHUNG & SCHLAFMEDEZIN Schwerin

    Schwerin, Germany

  • Siteworks - Zentrum für klinische Studien Hannover

    Hanover, Lower Saxony, Germany

  • Klinische Forschung Dresden | Dresden, Germany

    Dresden, Saxony, Germany

  • Osrodek Medycyny Snu Instytutu Psychiatrii i Neurologii

    Warsaw, Poland

  • EMC Instytut Medyczny SA

    Wroclaw, Poland

  • Hospital Universitario de La Ribera | Neurophysiology and Sleep Department

    Alzira, Spain

  • Centro Medico Teknon | Unidad de Medicina del Sueno

    Barcelona, Spain

  • Hospital Clinico San Carlos | Neurophysiology Department - Sleep Unit - Menopause Sleep Disturbance

    Madrid, Spain

  • Hospital Universitario HM Puerta Del Sur | Departamento de Ensayos Clinicos - Sleep Unit - Menopause Sleep Disturbance

    Móstoles, Spain

  • Hospital Universitario de Araba | Santiago Campus - Unidad Sueno

    Vitoria-Gasteiz, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.